The Stature of Human Thyroid Cancer Related to Over Expressed mir-221 and mir-146b

Molaei, Jamshid; Meidanchi, Melika; Mirzaahmadi, Sina

doi:10.4172/2155-9929.s2-030

Cited by 1 publication

(7 citation statements)

References 31 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, hemithyroidectomy compared to total thyroidectomy did not affect significantly the expression of miR-221, miR-222, and miR-146b at 1, 3, 6, and 12 months postoperatively (38). Similarly, Kondrotient et al supports the significantly reduced expression of miR-221 following hemi-thyroidectomy in PTC patients (46).…”

Section: Ptc Vs Benign Disease or Healthy Individualsmentioning

confidence: 83%

“…A total of 22 studies compared PTC against benign thyroid disease and healthy controls (16,27,(31)(32)(33)(34)(35)(36)(37)(38)(39)(40)(41)(42)(43)(44)(45)(46)(47)(48)(49)(50); six studies compared PTC to benign thyroid disease (28,(51)(52)(53)(54)(55), seven studies compared PTC to healthy controls (26,29,30,(56)(57)(58)(59), and four studies (24,(60)(61)(62) did not include healthy or benign thyroid disease comparison groups. A total of 108 miRNAs were investigated in the serum, plasma, or circulating exosomes (Table II).…”

Section: Ptc Vs Benign Disease or Healthy Individualsmentioning

confidence: 99%

“…The interval between the pre-and postoperative serum/plasma sampling of miRNA levels was 30 (16,33,37,46), 14 (39, 45), 14-42 (51,56) and 5-15 days (44), respectively. Two studies reported more than one postoperative serum/plasma miRNA measurements; at 1, 3, 6, and 12 months postoperatively (38) or at 1 and 3 months (30). The interval between pre-and post-operative sampling was not reported by the rest of the studies.…”

Section: Ptc Vs Benign Disease or Healthy Individualsmentioning

confidence: 99%

“…Lastly, four studies investigated the effect of surgery on the expression of circulating miRNAs in control groups (benign nodules) and reported that three miRNAs (miR-146a, miR-146b-5p and miR-222-3p) were significantly down-regulated in the postoperative period (38,45,51,56).…”

Section: Ptc Vs Benign Disease or Healthy Individualsmentioning

confidence: 99%

“…Twelve studies investigated the association between miRNA levels and extrathyroid extension of PTC (27,30,32,33,37,38,40,45,46,51,54,59). Eight miRNAs did not change significantly in tumors with extrathyroidal extension compared to those without extension.…”

Section: Extrathyroidal Extensionmentioning

confidence: 99%

See 4 more Smart Citations

Circulating microRNAs and Clinicopathological Findings of Papillary Thyroid Cancer: A Systematic Review

Geropoulos

Psarras

Papaioannou

et al. 2022

In Vivo

View full text Add to dashboard Cite

Background/Aim: Papillary thyroid cancer (PTC) is the most common endocrine malignancy with a rising incidence. There is a need for a non-invasive preoperative test to enable better patient counselling. The aim of this systematic review was to investigate the potential role of circulating microRNAs (miRNAs) in the diagnosis and prognosis of PTC. Materials and Methods: A systematic literature search was performed using MEDLINE, Cochrane, and Scopus databases (last search date was December 1, 2021). Studies investigating the expression of miRNAs in the serum or plasma of patients with PTC were deemed eligible for inclusion. Results: Among the 1,533 screened studies, 39 studies met the inclusion criteria. In total, 108 miRNAs candidates were identified in the serum, plasma, or exosomes of patients suffering from PTC. Furthermore, association of circulating miRNAs with thyroid cancer-specific clinicopathological features, such as tumor size (13 miRNAs), location (3 miRNAs), extrathyroidal extension (9 miRNAs), pre-vs. postoperative period (31 miRNAs), lymph node metastasis (17 miRNAs), TNM stage (9 miRNAs), BRAF V600E mutation (6 miRNAs), serum thyroglobulin levels (2 miRNAs), 131 I avid metastases (13 miRNAs), and tumor recurrence (2 miRNAs) was also depicted in this study. Conclusion: MiRNAs provide a potentially promising role in the diagnosis and prognosis of PTC. There is a correlation between miRNA expression profiles and specific clinicopathological features of PTC. However, to enable their use in clinical practice, further clinical studies are required to validate the predictive value and utility of miRNAs as biomarkers.Thyroid cancer is the 20 th most common cancer in the UK, and the incidence rates are projected to rise to 74% by the year 2035 (1). Papillary thyroid carcinoma (PTC) is the most common histological type, accounting for approximately 80% of the cases (2). Although, the vast majority of patients presenting with thyroid nodules that are benign, the ability to characterize the malignant nodules is quite important to ensure appropriate patient counselling when discussing curative therapy and the extent of the primary resection (3).

show abstract

Section: Ptc Vs Benign Disease or Healthy Individualsmentioning

confidence: 83%